Hypertension in mice with transgenic activation of the brain renin-angiotensin system is vasopressin dependent

American Journal of Physiology - Regulatory Integrative and Comparative Physiology

Volumn 304, Issue 10, 2013, Pages

  Littlejohn, Nicole K ^a   Siel, Rick B ^a   Ketsawatsomkron, Pimonrat ^a   Pelham, Christopher J ^a   Pearson, Nicole A ^a   Hilzendeger, Aline M ^a   Buehrer, Beth A ^a   Weidemann, Benjamin J ^a   Li, Huiping ^a   Davis, Deborah R ^a   Thompson, Anthony P ^a   Liu, Xuebo ^a   Cassell, Martin D ^a   Sigmund, Curt D ^a   Grobe, Justin L ^a  

^a UNIVERSITY OF IOWA   (United States)

Author keywords

Antidiuretic hormone; Vaprisol

Indexed keywords

ACETYLCHOLINE; ANGIOTENSIN II; ANGIOTENSINOGEN; AQUAPORIN 2; ARGIPRESSIN; CONIVAPTAN; ENDOTHELIN 1; NITROPRUSSIDE SODIUM; PHENYLEPHRINE; PROSTAGLANDIN F2 ALPHA; RENIN; TOLVAPTAN; VASOPRESSIN; VASOPRESSIN V2 RECEPTOR;

ABDOMINAL AORTA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE REGULATION; BLOOD VESSEL REACTIVITY; CARDIOVASCULAR FUNCTION; CONTROLLED STUDY; FEMALE; FLUID BALANCE; GENE ACTIVATION; GENOTYPE; HYPERTENSION; HYPONATREMIA; IMMUNOCOMPETENT CELL; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MALE; MESENTERIC ARTERY; METABOLIC REGULATION; MOUSE; NONHUMAN; PHYSICAL ACTIVITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN URINE LEVEL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SUPRAOPTIC NUCLEUS; SYSTOLIC BLOOD PRESSURE; TELEMETRY; TRANSGENICS; VASCULAR RESISTANCE; VASCULAR RING;

EID: 84878651210     PISSN: 03636119     EISSN: 15221490     Source Type: Journal    
DOI: 10.1152/ajpregu.00082.2013     Document Type: Article

References (77)

1. Aoyagi T, Koshimizu TA, Tanoue A. Vasopressin regulation of blood pressure and volume: findings from V1a receptor-deficient mice. Kidney Int 76: 1035-1039, 2009.
2. Argent NB, Burrell LM, Goodship TH, Wilkinson R, Baylis PH. Osmoregulation of thirst and vasopressin release in severe chronic renal failure. Kidney Int 39: 295-300, 1991.
3. Bakris G, Bursztyn M, Gavras I, Bresnahan M, Gavras H. Role of vasopressin in essential hypertension: racial differences. J Hypertens 15: 545-550, 1997.
4. Bonjour JP, Malvin RL. Stimulation of ADH release by the reninangiotensin system. Am J Physiol 218: 1555-1559, 1970.
5. Burnatowska-Hledin M, Zeneberg A, Roulo A, Grobe J, Zhao P, Lelkes PI, Clare P, Barney C. Expression of VACM-1 protein in cultured rat adrenal endothelial cells is linked to the cell cycle. Endothelium 8: 49-63, 2001.
6. Burnatowska-Hledin M, Zhao P, Capps B, Poel A, Parmelee K, Mungall C, Sharangpani A, Listenberger L. VACM-1, a cullin gene family member, regulates cellular signaling. Am J Physiol Cell Physiol 279: C266-C273, 2000.
7. Burrell LM, Risvanis J, Johnston CI, Naitoh M, Balding LC. Vasopressin receptor antagonism-a therapeutic option in heart failure and hypertension. Exp Physiol 85 Spec No: 259S-265S, 2000.
8. Calò LA, Pagnin E, Davis PA, Sartori M, Ceolotto G, Pessina AC, Semplicini A. Increased expression of regulator of G protein signaling-2 (RGS-2) in Bartter's/Gitelman's syndrome. A role in the control of vascular tone and implication for hypertension. J Clin Endocrinol Metab 89: 4153-4157, 2004.
9. Campos LA, Couto AS, Iliescu R, Santos JA, Santos RA, Ganten D, Campagnole-Santos MJ, Bader M, Baltatu O. Differential regulation of central vasopressin receptors in transgenic rats with low brain angiotensinogen. Regul Pept 119: 177-182, 2004.
10. Coleman CG, Anrather J, Iadecola C, Pickel VM. Angiotensin II type 2 receptors have a major somatodendritic distribution in vasopressincontaining neurons in the mouse hypothalamic paraventricular nucleus. Neuroscience 163: 129-142, 2009.
11. Crofton JT, Share L, Shade RE, Lee-Kwon WJ, Manning M, Sawyer WH. The importance of vasopressin in the development and maintenance of DOC-salt hypertension in the rat. Hypertension 1: 31-38, 1979.
12. da Silva AQ, Fontes MA, Kanagy NL. Chronic infusion of angiotensin receptor antagonists in the hypothalamic paraventricular nucleus prevents hypertension in a rat model of sleep apnea. Brain Res 1368: 231-238, 2011.
13. Davisson RL, Yang G, Beltz TG, Cassell MD, Johnson AK, Sigmund CD. The brain renin-angiotensin system contributes to the hypertension in mice containing both the human renin and human angiotensinogen transgenes. Circ Res 83: 1047-1058, 1998.
14. de Oliveira-Sales EB, Nishi EE, Boim MA, Dolnikoff MS, Bergamaschi CT, Campos RR. Upregulation of AT1R and iNOS in the rostral ventrolateral medulla (RVLM) is essential for the sympathetic hyperactivity and hypertension in the 2K-1C Wistar rat model. Am J Hypertens 23: 708-715, 2010.
15. de Paula RB, Plavnik FL, Rodrigues CI, Neves Fde A, Kohlmann O, Jr, Ribeiro AB, Gavras I, Gavras H. Contribution of vasopressin to orthostatic blood pressure maintenance in essential hypertension. Am J Hypertens 6: 794-798, 1993.
16. Fay MJ, Du J, Yu X, North WG. Evidence for expression of vasopressin V2 receptor mRNA in human lung. Peptides 17: 477-481, 1996.
17. Gagnon DJ, Cousineau D, Boucher PJ. Release of vasopressin by angiotensin II and prostaglandin E2 from the rat neuro-hypophysis in vitro. Life Sci 12: 487-497, 1973.
18. Gassanov N, Semmo N, Semmo M, Nia AM, Fuhr U, Er F. Arginine vasopressin (AVP) and treatment with arginine vasopressin receptor antagonists (vaptans) in congestive heart failure, liver cirrhosis and syn- drome of inappropriate antidiuretic hormone secretion (SIADH). Eur J Clin Pharmacol 67: 333-346, 2011.
19. Gavras H. Pressor systems in hypertension and congestive heart failure. Role of vasopressin. Hypertension 16: 587-593, 1990.
20. Gózdz A, Szczepanska-Sadowska E, Szczepanska K, Maslinski W, Luszczyk B. Vasopressin V1a, V1b and V2 receptors mRNA in the kidney and heart of the renin transgenic TGR(mRen2)27 and Sprague Dawley rats. J Endocrinol 176: 111-119, 2003.
21. Grobe JL, Grobe CL, Beltz TG, Westphal SG, Morgan DA, Xu D, de Lange WJ, Li H, Sakai K, Thedens DR, Cassis LA, Rahmouni K, Mark AL, Johnson AK, Sigmund CD. The brain renin-angiotensin system controls divergent efferent mechanisms to regulate fluid and energy balance. Cell Metab 12: 431-442, 2010.
22. Grobe JL, Xu D, Sigmund CD. An intracellular renin-angiotensin system in neurons: fact, hypothesis, or fantasy. Physiology (Bethesda) 23: 187-193, 2008.
23. Gu S, Anton A, Salim S, Blumer KJ, Dessauer CW, Heximer SP. Alternative translation initiation of human regulators of G-protein signaling- 2 yields a set of functionally distinct proteins. Mol Pharmacol 73: 1-11, 2008.
24. Halabi CM, Beyer AM, de Lange WJ, Keen HL, Baumbach GL, Faraci FM, Sigmund CD. Interference with PPAR gamma function in smooth muscle causes vascular dysfunction and hypertension. Cell Metab 7: 215-226, 2008.
25. Hao J, Michalek C, Zhang W, Zhu M, Xu X, Mende U. Regulation of cardiomyocyte signaling by RGS proteins: differential selectivity towards G proteins and susceptibility to regulation. J Mol Cell Cardiol 41: 51-61, 2006.
26. Head GA, Mayorov DN. Central angiotensin and baroreceptor control of circulation. Ann NY Acad Sci 940: 361-379, 2001.
27. Heximer SP, Knutsen RH, Sun X, Kaltenbronn KM, Rhee MH, Peng N, Oliveira-dos-Santos A, Penninger JM, Muslin AJ, Steinberg TH, Wyss JM, Mecham RP, Blumer KJ. Hypertension and prolonged vasoconstrictor signaling in RGS2-deficient mice. J Clin Invest 111: 445-452, 2003.
28. Heximer SP, Watson N, Linder ME, Blumer KJ, Hepler JR. RGS2/ G0S8 is a selective inhibitor of Gqalpha function. Proc Natl Acad Sci USA 94: 14389-14393, 1997.
29. Huang BS, Leenen FH. Both brain angiotensin II and "ouabain" contribute to sympathoexcitation and hypertension in Dahl S rats on high salt intake. Hypertension 32: 1028-1033, 1998.
30. Iovino M, Steardo L. Vasopressin release to central and peripheral angiotensin II in rats with lesions of the subfornical organ. Brain Res 322: 365-368, 1984.
31. Itaya Y, Suzuki H, Matsukawa S, Kondo K, Saruta T. Central reninangiotensin system and the pathogenesis of DOCA-salt hypertension in rats. Am J Physiol Heart Circ Physiol 251: H261-H268, 1986.
32. Johren O, Imboden H, Hauser W, Mave I, Sanvitto GL, Saavedra JM. Localization of angiotensin-converting enzyme,angiotensin II, angiotensin II receptor subtypes, and vasopressin in the mouse hypothalamus. Brain Res 757: 218-227, 1997.
33. Kato Y, Igarashi N, Hirasawa A, Tsujimoto G, Kobayashi M. Distribution and developmental changes in vasopressin V2 receptor mRNA in rat brain. Differentiation 59: 163-169, 1995.
34. Knepel W, Anhut H, Nutto D, Holland A, Meyer DK. Vasopressin release from rat medial basal hypothalamus induced in vitro by angiotensin. Eur J Pharmacol 80: 247-249, 1982.
35. Knepel W, Nutto D, Meyer DK. Effect of transection of subfornical organ efferent projections on vasopressin release induced by angiotensin or isoprenaline in the rat. Brain Res 248: 180-184, 1982.
36. Koshimizu TA, Nasa Y, Tanoue A, Oikawa R, Kawahara Y, Kiyono Y, Adachi T, Tanaka T, Kuwaki T, Mori T, Takeo S, Okamura H, Tsujimoto G. V1a vasopressin receptors maintain normal blood pressure by regulating circulating blood volume and baroreflex sensitivity. Proc Natl Acad Sci USA 103: 7807-7812, 2006.
37. Kubo T, Yamaguchi H, Tsujimura M, Hagiwara Y, Fukumori R. An angiotensin system in the anterior hypothalamic area anterior is involved in the maintenance of hypertension in spontaneously hypertensive rats. Brain Res Bull 52: 291-296, 2000.
38. Kubo T, Yamaguchi H, Tsujimura M, Hagiwara Y, Fukumori R. Blockade of angiotensin receptors in the anterior hypothalamic preoptic area lowers blood pressure in DOCA-salt hypertensive rats. Hypertens Res 23: 109-118, 2000.
39. Laragh JH. Biochemical profiling and the natural history of hypertensive diseases: low-renin essential hypertension, a benign condition. Circulation 44: 971-974, 1971.
40. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25: 402-408, 2001.
41. Matsuguchi H, Schmid PG. Acute interaction of vasopressin and neurogenic mechanisms in DOC-salt hypertension. Am J Physiol Heart Circ Physiol 242: H37-H43, 1982.
42. Mayorov DN, Head GA. AT1 receptors in the RVLM mediate pressor responses to emotional stress in rabbits. Hypertension 41: 1168-1173, 2003.
43. Möhring J, Möhring B. Reevaluation of DOCA escape phenomenon. Am J Physiol 223: 1237-1245, 1972.
44. Morimoto S, Cassell MD, Sigmund CD. The brain renin-angiotensin system in transgenic mice carrying a highly regulated human renin transgene. Circ Res 90: 80-86, 2002.
45. Neves MF, Virdis A, Schiffrin EL. Resistance artery mechanics and composition in angiotensin II-infused rats: effects of aldosterone antagonism. J Hypertens 21: 189-198, 2003.
46. Northcott CA, Watts S, Chen Y, Morris M, Chen A, Haywood JR. Adenoviral inhibition of AT1a receptors in the paraventricular nucleus inhibits acute increases in mean arterial blood pressure in the rat. Am J Physiol Regul Integr Comp Physiol 299: R1202-R1211, 2010.
47. Oparil S, Yang RH, Jin HG, Chen SJ, Meng QC, Berecek KH, Wyss JM. Role of anterior hypothalamic angiotensin II in the pathogenesis of salt sensitive hypertension in the spontaneously hypertensive rat. Am J Med Sci 307: S26-S37, 1994.
48. Os I, Kjeldsen SE, Skjøtø J, Westheim A, Lande K, Aakesson I, Frederichsen P, Leren P, Hjermann I, Eide IK. Increased plasma vasopressin in low renin essential hypertension. Hypertension 8: 506-513, 1986.
49. Padfield PL, Brown JJ, Lever AF, Morton JJ, Robertson JI. Blood pressure in acute and chronic vasopressin excess: studies of malignant hypertension and the syndrome of inappropriate antidiuretic hormone secretion. N Engl J Med 304: 1067-1070, 1981.
50. Park CG, Leenen FH. Effects of centrally administered losartan on deoxycorticosterone-salt hypertension rats. J Korean Med Sci 16: 553-557, 2001.
51. Phillips MI. Angiotensin in the brain. Neuroendocrinology 25: 354-377, 1978.
52. Raggenbass M. Overview of cellular electrophysiological actions of vasopressin. Eur J Pharmacol 583: 243-254, 2008.
53. Ramsay DJ. Effects of circulating angiotensin II on the brain. In: Frontiers in Neuroendocrinology, edited by Ganong WF and Martini L. New York: Raven, 1982, vol. 7, p. 263-285.
54. Sakai K, Agassandian K, Morimoto S, Sinnayah P, Cassell MD, Davisson RL, Sigmund CD. Local production of angiotensin II in the subfornical organ causes elevated drinking. J Clin Invest 117: 1088-1095, 2007.
55. Salim S, Sinnarajah S, Kehrl JH, Dessauer CW. Identification of RGS2 and type V adenylyl cyclase interaction sites. J Biol Chem 278: 15842-15849, 2003.
56. Schinke M, Baltatu O, Böhm M, Peters J, Rascher W, Bricca G, Lippoldt A, Ganten D, Bader M. Blood pressure reduction and diabetes insipidus in transgenic rats deficient in brain angiotensinogen. Proc Natl Acad Sci USA 96: 3975-3980, 1999.
57. Semplicini A, Lenzini L, Sartori M, Papparella I, Calò LA, Pagnin E, Strapazzon G, Benna C, Costa R, Avogaro A, Ceolotto G, Pessina AC. Reduced expression of regulator of G-protein signaling 2 (RGS2) in hypertensive patients increases calcium mobilization and ERK1/2 phosphorylation induced by angiotensin II. J Hypertens 24: 1115-1124, 2006.
58. Shi P, Diez-Freire C, Jun JY, Qi Y, Katovich MJ, Li Q, Sriramula S, Francis J, Sumners C, Raizada MK. Brain microglial cytokines in neurogenic hypertension. Hypertension 56: 297-303, 2010.
59. Sinn PL, Zhang X, Sigmund CD. JG cell expression and partial regulation of a human renin genomic transgene driven by a minimal renin promoter. Am J Physiol Renal Physiol 277: F634-F642, 1999.
60. Sun X, Kaltenbronn KM, Steinberg TH, Blumer KJ. RGS2 is a mediator of nitric oxide action on blood pressure and vasoconstrictor signaling. Mol Pharmacol 67: 631-639, 2005.
61. Sun Z, Cade R, Morales C. Role of central angiotensin II receptors in cold-induced hypertension. Am J Hypertens 15: 85-92, 2002.
62. Szczepanska-Sadowska E, Paczwa P, Lon S, Ganten D. Increased pressor function of central vasopressinergic system in hypertensive renin transgenic rats. J Hypertens 16: 1505-1514, 1998.
63. Szinnai G, Morgenthaler NG, Berneis K, Struck J, Müller B, Keller U, Christ-Crain M. Changes in plasma copeptin, the c-terminal portion of arginine vasopressin during water deprivation and excess in healthy subjects. J Clin Endocrinol Metab 92: 3973-3978, 2007.
64. Takimoto E, Koitabashi N, Hsu S, Ketner EA, Zhang M, Nagayama T, Bedja D, Gabrielson KL, Blanton R, Siderovski DP, Mendelsohn ME, Kass DA. Regulator of G protein signaling 2 mediates cardiac compensation to pressure overload and antihypertrophic effects of PDE5 inhibition in mice. J Clin Invest 119: 408-420, 2009.
65. Tang KM, Wang GR, Lu P, Karas RH, Aronovitz M, Heximer SP, Kaltenbronn KM, Blumer KJ, Siderovski DP, Zhu Y, Mendelsohn ME. Regulator of G-protein signaling-2 mediates vascular smooth muscle relaxation and blood pressure. Nat Med 9: 1506-1512, 2003.
66. Trinder D, Phillips PA, Stephenson JM, Risvanis J, Aminian A, Adam W, Cooper M, Johnston CI. Vasopressin V1 and V2 receptors in diabetes mellitus. Am J Physiol Endocrinol Metab 266: E217-E223, 1994.
67. Tsang S, Woo AY, Zhu W, Xiao RP. Deregulation of RGS2 in cardiovascular diseases. Front Biosci (Schol Ed) 2: 547-557, 2010.
68. Wrobel LJ, Dupré A, Raggenbass M. Excitatory action of vasopressin in the brain of the rat: role of cAMP signaling. Neuroscience 172: 177-186, 2011.
69. Yamamoto J, Yamane Y, Umeda Y, Yoshioka T, Nakai M, Ikeda M. Cardiovascular hemodynamics and vasopressin blockade in DOCA-salt hypertensive rats. Hypertension 6: 397-407, 1984.
70. Yang CR, Phillips MI, Renaud LP. Angiotensin II receptor activation depolarizes rat supraoptic neurons in vitro. Am J Physiol Regul Integr Comp Physiol 263: R1333-R1338, 1992.
71. Yang J, Kamide K, Kokubo Y, Takiuchi S, Tanaka C, Banno M, Miwa Y, Yoshii M, Horio T, Okayama A, Tomoike H, Kawano Y, Miyata T. Genetic variations of regulator of G-protein signaling 2 in hypertensive patients and in the general population. J Hypertens 23: 1497-1505, 2005.
72. Yang RH, Jin H, Wyss JM, Oparil S. Depressor effect of blocking angiotensin subtype 1 receptors in anterior hypothalamus. Hypertension 19: 475-481, 1992.
73. Ye S, Zhong H, Duong VN, Campese VM. Losartan reduces central and peripheral sympathetic nerve activity in a rat model of neurogenic hypertension. Hypertension 39: 1101-1106, 2002.
74. Zhang W, Anger T, Su J, Hao J, Xu X, Zhu M, Gach A, Cui L, Liao R, Mende U. Selective loss of fine tuning of Gq/11 signaling by RGS2 protein exacerbates cardiomyocyte hypertrophy. J Biol Chem 281: 5811-5820, 2006.
75. Zhang X, Hense HW, Riegger GA, Schunkert H. Association of arginine vasopressin and arterial blood pressure in a population-based sample. J Hypertens 17: 319-324, 1999.
76. Zicha J, Kunes J, Lébl M, Pohlová I, Slaninová J, Jelínek J. Antidiuretic and pressor actions of vasopressin in age-dependent DOCA-salt hypertension. Am J Physiol Regul Integr Comp Physiol 256: R138-R145, 1989.
77. Zimmerman MC, Lazartigues E, Sharma RV, Davisson RL. Hypertension caused by angiotensin II infusion involves increased superoxide production in the central nervous system. Circ Res 95: 210-216, 2004.